Friday Morning Pre-Market Insights: FireEye Inc (FEYE), GoPro Inc (GPRO), Synergy Pharmaceuticals Inc (SGYP), LinkedIn Corp (LNKD)

FireEye Inc (NASDAQ:FEYE) shares are falling 3.83% to $45.93 in pre-market trading, after the cybersecurity company reported a second quarter adjusted loss of $0.41 per share after the markets closed Thursday, compared to the loss of $0.55 per share last year. In conjunction with the earnings release, the company also announced the resignation of its CFO, Michael Sheridan. FBR Capital analyst Daniel Ives noted that the resignation is a non-event in his view as CEO David DeWalt remains the face of FireEye on the Street. As of this writing, 9 analysts are bullish on FireEye and 9 are neutral, according to TipRanks. The average 12-month price target on the stock is $50.89, marking a 6.55% potential upside from where the stock last closed.

GoPro Inc (NASDAQ:GPRO) shares increased 3.45% to $63.82 in pre-market trading after Citigroup analyst Jeremy David upgraded GPRO from a Neutral to a Buy rating with a price target of $90, which represents a potential upside of 46% from Thursday’s closing price. According to TipRanks, which measures analysts’ and bloggers’ success rate based on how their calls perform, David has a total average return of -1.1% and a 55.6% success rate. David has a -12.0% average return when recommending GPRO, and is ranked #2758 out of 3755 analysts. Out of the 14 analysts polled by TipRanks, 10 rate GoPro stock a Buy, while 4 rate the stock a Hold. With a return potential of 27.09%, the stock’s 12-month consensus target price stands at $78.40. Additionally, the action camera giant recently reached 6-month highs after posting second quarter earnings results that beat expectations.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) shares are up 2.44% to $8.80 in pre-market trading, adding to their 4.63% increase yesterday, after the company announced positive trial results for its pipeline drug, plecanatide, which aims to treat patients with chronic idiopathic constipation. The second of pivotal phase 3 trial assessed the safety and efficacy of two different doses of the drug. Preliminary data suggests that both doses met the primary endpoint of the study with statistical significance. Both doses proved to be safe and well-tolerated in patients, with the most common side effect being diarrhea. As of this writing, all the four analysts polled by TipRanks are bullish on Synergy stock.The average 12-month price target on the stock is $16.50, marking over a 90% potential upside from where SGYP is currently trading.

LinkedIn Corp (NYSE:LNKD) shares fell more than 5% in pre-market trading to $215.37 after the business networking giant reported better than expected second-quarter results, but lowered organic H2 guidance, citing ongoing weakness in its high-margin Display Advertising segment. Piper Jaffray analyst Gene Munster believes that the shares are down as a result of investors backing out the outperformance of Lynda and the mixed guide for the core in 2H15 with some weakness in Marketing Services vs strength in Talent Solutions. According to TipRanks’s data, 20 out of 24 analysts who cover LinkedIn stock rate it as a Buy, 3 rate it as a Hold, and only one rates it as a Sell. The 12-month month price objective on the stock is $251.47, which represents upside potential of 10.71% from where the stock last closed.



Stay Ahead of Everyone Else

Get The Latest Stock News Alerts